Ensartinib: all 34 studies that test it
Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.RecruitingNCT07448116Phase 1/2
- Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)RecruitingNCT07354061Phase 1/2
- Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLCNot yet recruitingNCT07235306Phase 2
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingNCT06955325Phase 3
- Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical StudyNot yet recruitingNCT06785584Phase 4
- Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRDNot yet recruitingNCT06780839Phase 2
- Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung CancerNot yet recruitingNCT06779539Phase 2
- The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk FactorsNot yet recruitingNCT06772610Phase 2
- Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung CancerNot yet recruitingNCT06762327Phase 2
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingNCT06563999Phase 2
- A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy VolunteersNot yet recruitingNCT06492525Phase 1
- Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerRecruitingNCT05341583Phase 3
- Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerRecruitingNCT05241028Phase 2
- A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerNot yet recruitingNCT05186506Phase 2
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
- Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
- Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerCompletedNCT02898116Phase 1/2Results posted
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerCompletedNCT01625234Phase 1/2Results posted
- A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted ConditionsCompletedNCT05665283Phase 1
- Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationActive, not recruitingNCT05491811Phase 2
- A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung CancerStatus unknownNCT05380024Phase 2
- Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI ResistanceStatus unknownNCT05178511Phase 2
- Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerActive, not recruitingNCT04837716Phase 1
- X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesStatus unknownNCT04415320Phase 2
- The Absorption, Metabolism and Excretion of [14C]Ensartinib in HumanStatus unknownNCT03804541Phase 1
- X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesActive, not recruitingNCT03753685Phase 2
- X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene RearrangementStatus unknownNCT03608007Phase 2
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownNCT03574402Phase 2
- Bioequivalency Study of Ensartinib Capsules in Healthy VolunteersCompletedNCT03536481Phase 1
- Treating Patients With Melanoma and ALK Alterations With EnsartinibActive, not recruitingNCT03420508Phase 2
- X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibActive, not recruitingNCT03215693Phase 2
- Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKCompletedNCT02959619Phase 1
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Phase 3